J. Howl, I. D. Nicholl, and S. Jones, The many futures for cell-penetrating peptides: how soon is now?, Biochemical Society Transactions, vol.35, issue.4, pp.767-769, 2007.
DOI : 10.1042/BST0350767

A. Joliot, C. Pernelle, H. Deagostini-bazin, and A. Prochiantz, Antennapedia homeobox peptide regulates neural morphogenesis., Proceedings of the National Academy of Sciences, vol.88, issue.5, pp.1864-1868, 1991.
DOI : 10.1073/pnas.88.5.1864

D. Derossi, A. H. Joliot, G. Chassaing, and A. Prochiantz, The third helix of the Antennapedia homeodomain translocates through biological membranes, J Biol Chem, vol.269, pp.10444-10450, 1994.

D. Derossi, G. Chassaing, and A. Prochiantz, Trojan peptides: the penetratin system for intracellular delivery, Trends in Cell Biology, vol.8, issue.2, pp.84-87, 1998.
DOI : 10.1016/S0962-8924(98)80017-2

M. Mae and U. Langel, Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery, Current Opinion in Pharmacology, vol.6, issue.5, pp.509-514, 2006.
DOI : 10.1016/j.coph.2006.04.004

M. Zorko and U. Langel, Cell-penetrating peptides: mechanism and kinetics of cargo delivery Advanced drug delivery reviews, pp.529-545, 2005.

J. Temsamani and P. Vidal, The use of cell-penetrating peptides for drug delivery. Drug discovery today, pp.1012-1019, 2004.

Z. Fajloun, R. Kharrat, L. Chen, C. Lecomte, E. Di-luccio et al., Chemical synthesis and characterization of maurocalcine, p.24

E. Esteve, K. Mabrouk, A. Dupuis, S. Smida-rezgui, X. Altafaj et al., Transduction of the Scorpion Toxin Maurocalcine into Cells: EVIDENCE THAT THE TOXIN CROSSES THE PLASMA MEMBRANE, Journal of Biological Chemistry, vol.280, issue.13, pp.12833-12839, 2005.
DOI : 10.1074/jbc.M412521200
URL : https://hal.archives-ouvertes.fr/hal-00067701

M. Darbon, M. D. Ronjat, and . Waard, Critical amino acid residues of maurocalcine involved in pharmacology, lipid interaction and cell penetration
URL : https://hal.archives-ouvertes.fr/inserm-00378029

A. Mosbah, R. Kharrat, Z. Fajloun, J. G. Renisio, E. Blanc et al., A new fold in the scorpion toxin family, associated with an activity on a ryanodine-sensitive calcium channel, Proteins: Structure, Function, and Genetics, vol.7, issue.3, pp.436-442, 2000.
DOI : 10.1002/1097-0134(20000815)40:3<436::AID-PROT90>3.0.CO;2-9

G. Drinand and J. Temsamani, Translocation of protegrin I through phospholipid membranes: role of peptide folding, Biochim Biophys Acta, vol.1559, pp.160-170, 2002.

J. M. Ronjat, H. Sabatier, V. Darbon, M. D. Jacquemond, and . Waard, Design of a disulfide-less, pharmacologically-inert and chemically-competent analog 25

G. Bonadonna, M. Zambetti, A. Moliterni, L. Gianni, and P. Valagussa, Clinical Relevance of Different Sequencing of Doxorubicin and Cyclophosphamide, Methotrexate, and Fluorouracil in Operable Breast Cancer, Journal of Clinical Oncology, vol.22, issue.9, pp.1614-1620, 2004.
DOI : 10.1200/JCO.2004.07.190

M. Colozza, E. De-azambuja, F. Cardoso, C. Bernard, and M. J. Piccart, Breast Cancer: Achievements in Adjuvant Systemic Therapies in the Pre-Genomic Era, The Oncologist, vol.11, issue.2, pp.111-125, 2006.
DOI : 10.1634/theoncologist.11-2-111

. Wu, A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system, J Pharmacol Exp Ther, vol.317, pp.1372-1381, 2006.

. Gottesman, Targeting multidrug resistance in cancer, Nat Rev Drug Discov, vol.5, pp.219-234, 2006.

. Craven, A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells, Mol Pharmacol, vol.68, pp.1747-1756, 2005.

M. De-la-torre, X. Y. Hao, R. Larsson, P. Nygren, T. Tsuruo et al., Characterization of four doxorubicin adapted human breast cancer lactosaminated albumin: Effects on rats with liver fibrosis and cirrhosis. Dig Liver Dis, pp.404-408, 2006.

J. F. Liang and V. C. Yang, Synthesis of doxorubicin???peptide conjugate with multidrug resistant tumor cell killing activity, Bioorganic & Medicinal Chemistry Letters, vol.15, issue.22, pp.5071-5075, 2005.
DOI : 10.1016/j.bmcl.2005.07.087

K. R. Hande, Clinical applications of anticancer drugs targeted to topoisomerase II, Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, vol.1400, issue.1-3, pp.173-184, 1998.
DOI : 10.1016/S0167-4781(98)00134-1

F. Shen, S. Chu, A. K. Bence, B. Bailey, X. Xue et al., Quantitation of Doxorubicin Uptake, Efflux, and Modulation of Multidrug Resistance (MDR) in MDR Human Cancer Cells, Journal of Pharmacology and Experimental Therapeutics, vol.324, issue.1, pp.95-102, 2008.
DOI : 10.1124/jpet.107.127704

S. Modok, H. R. Mellor, and R. Callaghan, Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer, Current Opinion in Pharmacology, vol.6, issue.4, pp.350-354, 2006.
DOI : 10.1016/j.coph.2006.01.009

F. J. Sharom, ABC multidrug transporters: structure, function and role in chemoresistance, Pharmacogenomics, vol.9, issue.1, pp.105-127, 2008.
DOI : 10.2217/14622416.9.1.105

D. Nielsen, C. Maare, and T. Skovsgaard, Cellular resistance to anthracyclines, General Pharmacology: The Vascular System, vol.27, issue.2, pp.251-255, 1996.
DOI : 10.1016/0306-3623(95)02013-6

G. J. Schuurhuis, T. H. Van-heijningen, A. Cervantes, H. M. Pinedo, J. H. De-lange et al., Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells, British Journal of Cancer, vol.68, issue.5, pp.898-908, 1993.
DOI : 10.1038/bjc.1993.452

L. I. Mclellan and C. R. Wolf, Glutathione and glutathione-dependent enzymes in cancer drug resistance, Drug Resistance Updates, vol.2, issue.3, pp.153-164, 1999.
DOI : 10.1054/drup.1999.0083

M. Beers, E. Heijn, K. Boven, H. M. Hoekman, and . Pinedo, A doxorubicin- CNGRC-peptide conjugate with prodrug properties, Biochem Pharmacol, vol.63, pp.897-908, 2002.

J. M. Mikati, M. Sabatier, J. Ronjat, M. D. Fantini, and . Waard, Cell penetration properties of maurocalcine, a natural venom peptide active on the intracellular ryanodine receptor, Biochim Biophys Acta, vol.1758, pp.308-319, 2006.
URL : https://hal.archives-ouvertes.fr/inserm-00394156

R. H. Petrovic and . Costa, A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment, J Clin Invest, vol.117, pp.99-111, 2007.

R. Santos, B. Silva, E. Acevedo, V. Lopez, D. F. Falcon et al., Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2), Cancer Res, vol.64, pp.7127-7129, 2004.

Y. Kageyama and . Tanaka, Effect of synthetic cell-penetrating peptides on TrkA activity in PC12 cells, J Pharmacol Sci, vol.106, pp.107-113, 2008.